International multi-centre clinical trials in kidney disease: ACTIVE trial & RESOLVE trial
Despite the availability of life-preserving haemodialysis, people with end stage kidney disease do not have the same life expectancy as people with normal kidney disease. Quality of life is impaired with patients typically experiencing an increased burden of symptoms including fatigue, lethargy, loss of appetite and itch. This talk will review trials designed to improve meaningful clinical outcomes for people living with dialysis. Haemodialysis as it is conventionally practiced only delivers the biochemical equivalent of 10% of normal kidney function. The ACTIVE trial tested whether increasing that biochemical equivalent would improve quality of life. RESOLVE will examine whether addressing the impaired salt and water clearance of end stage kidney disease will improve cardiovascular outcomes.